

**UNIVERSITY OF MARYLAND
SCHOOL OF MEDICINE**

DEPARTMENT OF NEUROLOGY

University of Maryland Hospital, Room N4W46
22 South Greene Street
Baltimore, Maryland 21201-1595
Telephone: 410-605-7061
FAX: 410-605-7937
e-mail: cbever@umaryland.edu

Christopher T. Bever, Jr., M.D.
Professor
1627 99 MAR 24 P2:12

December 15, 1998


Kimberly Popper
Center for Drug Evaluation & Research (HFD21)
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Re: Compounding of 4-aminopyridine and 3,4 diaminopyridine

Dear Ms. Popper:

I am writing to request that I be included in the deliberations on the continued availability of 4-aminopyridine and 3,4 diaminopyridine through compounding pharmacies. I am an academic neurologist who specializes in the care of multiple sclerosis patients. I have had a particular interest in the use of potassium channel blockers such as 4-aminopyridine and 3,4 diaminopyridine as a symptomatic treatment for MS. I have conducted and published several studies of both agents and have had the opportunity to follow a group of MS patients on chronic treatment. These studies have been carried out under using an FDA approved source of drug under FDA supervision. Although I am aware that both drugs are available through compounding pharmacies I have rarely used these sources and have a number of reservations about these sources. I believe a review of the issues involved would be very helpful.

Sincerely yours,



Christopher T. Bever, Jr. M.D.
Professor of Neurology and
Pharmacology and Experimental Therapeutics

98N-0182

C110